Kornimate/medical-research-clean huggingface dataset:
assessment of growth factors levels associated with wound healing after soft tissue crown lengthening

Conditions: Gingival Overgrowth

Summary: clinicians often encounter the need for crown lengthening in the practice of dentistry and have to make treatment decisions taking into consideration how to best address the biological, functional, and esthetic requirements of each particular case. the concept of crown lengthening was first introduced by d.w. cohen (1962) and is presently a procedure that often employs some combination of tissue reduction or removal , osseous surgery , and/or orthodontics for tooth exposure and increasing the extent of supra gingival tooth structure for restoration of aesthetic purposes . gingivectomy and gingivoplasty considered kind of crown lengthening procedure. gingivectomy is defined as the excision of the soft tissue wall of a pocket. the procedure is usually combined with the recontouring of hyperplastic tissue by gingivectoplasty to restore physiological gingival form . gingivoplasty is a reshaping of the gingiva to create physiologic gingival contours, with the sole purpose of recontouring the gingiva in the absence of pockets. in doing so, the complete anatomical crown becomes exposed and pseudo pockets are eliminated creating a better environment for periodontal health. treatment options for crown lengthening procedures include: surgical, electrocautery or by laser. the aim of the present study was to compare the practical effectiveness and postoperative parameters of using diode laser and electrocautery for crown lengthening procedure.


Eligibility criteria:
inclusion criteria: 1. men and women aged ≥ 18 years. 2. patients with short clinical crowns to enhance esthetic, exposure of subgingival caries for prosthetic replacement, exposure of a fracture or combination. 3. all patients were free from any systemic diseases according to the criteria of modified cornell medical index. 4. all patients need soft tissue removal and don't need osseous resection. 5. full-mouth plaque score (fmps) ≤ 20% at baseline. 6. full-mouth bleeding score (fmbs) ≤ 20% at baseline. exclusion criteria: 1. light smokers i.e. smoking \> 10 cigarettes/day. 2. patients with medical conditions contraindicating surgical interventions. 3. pregnancy or lactation. 4. patients with active periodontal disease (pd ≥ 6 mm) 5. clinical and/or radiographic signs of periapical pathology. 6. patients with pacemakers.

Keywords: diode laser electrosurgery crown lengthening gingival crevicular fluid fibroblast growth factor platelet-derived growth factor transforming growth factor beta1
study of jitongning tablet to treat spondyloarthritis

Conditions: Spondyloarthritis

Summary: this study is to investigate the efficacy and safety of jitongning tablet in improving joint function and pain symptoms in active axial spondyloarthritis (spa) patients and to explore the optimal dosage.

jitongning tablet is a kind of traditional chinese medicine(tcm), consists of cortex eucommiae, duhuo(radix angelicae pubescentis), zhichuanwu(radix aconiti) , rhizoma corydalis, radix paeoniae rubra, radix puerariae and radix glycyrrhizae. this study is being conducted to evaluate the efficacy and safety of jitongning tablet in patients with active axial spondyloarthritis (spa) (syndrome of kidney yang deficiency and biood stasis stagnation), when compared with placebo and to explore the optimal dosage.

Eligibility criteria:
inclusion criteria: * men or women aged 18 to 65 years old (including 18 and 65) ; * meeting the diagnostic criteria for active axial spa according to the the asas classification 2009, defined as satisfied 2 of the following: 1. basdai score ≥ 4; 2. in the assessment of pain numerical rating scale (nrs), spine pain nrs ≥ 4; * meeting the standard of tcm syndrome diagnosis for kidney yang deficiency and biood stasis stagnating syndrome; * sacroiliac arthritis of ct categories i(a)\~ⅲ(b) (including i(a) and ⅲ(b)); * human leukocyte antigen b27 (hla-b27) is positive; * c-reactive protein (crp)/hypersensitive c-reactive protein (hscrp) and/or erythrocyte sedimentation rate raised; * voluntary signing of informed consent. exclusion criteria: * those who use nsaids in the first 2 weeks of randomization; * in the first 4 weeks of randomization, take disease-modifying antirheumatic chinese herbal medicine or chemical drugs (such as sulfasalazine ,methotrexate, leflunomide, chloroquine, total glycosides of tripterygium, cyclophosphamide, azathioprine, etc),opioid analgesics(methadone, morphine, etc.) ,systemic glucocorticoid therapy; * in the first 3 months of randomization, take biological agents that have been used for spinal arthritis; * those who have undergone spinal surgery or joint surgery within 8 weeks before randomization; * patients who received intra-articular injection, spinal or paravertebral injection of corticosteroids within the first 6 months of randomization; * the spine is completely stiff (fused); * any other rheumatic immune system diseases or immunodeficiency syndromes such as ulcerative colitis, psoriasis, uveitis, etc. * those who have a fertility requirement within 6 months; * women during pregnancy and lactation; * suspected or indeed drug use, substance abuse, alcoholism; * in the first 3 months of randomization, take the test or in progress; * serious cardiovascular, liver , kidney, brain, mental, neurological disorders that affect informed consent and/or adverse event expression or observation; * abnormal liver function(the ast or alt value is above the upper limit of the normal); abnormal renal function (serum creatinine is above the upper limit of normal); * due to other circumstances, the investigator considered it inappropriate for the participants.

Keywords: jitongning tablet, spondyloarthritis
an extension study to demonstrate long-term efficacy and safety of ct-p13 when co-administered with methotrexate in patient with rheumatoid arthritis who were treated with infliximab (remicade or ct-p13) in study ct-p13 3.1

Conditions: Rheumatoid Arthritis

Summary: ct-p13 (infliximab) is a monoclonal antibody currently being developed by celltrion, inc. this open-label, single-arm, multicenter, multiple single dose intravenous (iv) infusion, efficacy, and safety extension study of the phase 3 study ct-p13 3.1 is designed to assess the long-term efficacy and safety of multiple doses of ct-p13.


Eligibility criteria:
inclusion criteria: * patient who has completed the scheduled visits, including the end-of-study visit, in study ct-p13 3.1 * patient who has not had any major protocol violation in study ct-p13 3.1 * patient is permitted to enter the extension study if, in the option of their general practitioner or the investigator, the patient will continue to gain benefit from treatment in the extension study. local guidelines for patient treatment will be followed exclusion criteria: * patient who has been withdrawn from study ct-p13 3.1 for any reason * patient who, at the time of providing informed consent, has any ongoing medical issues such as serious adverse events (saes) or intolerance issues that mean continuation in this extension study could be detrimental to their health, in the opinion of the investigator * patient who plans to participate in a study with an investigational drug during the period of this extension study

Keywords: ra biosimilar
preliminary evaluation of the safety and tolerability of spot-mrna01 subcutaneously administered in healthy subjects

Conditions: Skin Aging

Summary: this is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and tolerability of spot-mrna01 injection in healthy adult volunteers.

spot-mrna01 (collagen 1 alpha 1 (col1a1) mrna-loaded by extracellular vesicles （evs）) can induce collagen protein grafts in dermal tissue, thereby supplementing collagen and reducing wrinkle formation in collagen-depleted skin. therefore, spotmrna01 can provide a source of human collagen intradermally for cosmetic anti-aging use. this is a first-in-human randomized, double-blind, placebo-controlled, single-dose, dose ascending, exploratory clinical study to evaluate the safety and tolerability of spot-mrna01 administered by subcutaneous injection to healthy adult volunteers. biopsies will be used to detect the expression of collagen in the skin of the injection area.

Eligibility criteria:
inclusion criteria: aged 18 to 75 years inclusive at the time of informed consent. exclusion criteria: 1. any transient or chronic skin condition, disorder, or infection within 20 cm of the target areas before treatment that, in the opinion of the investigator, may confound study results. 2. history of laser treatment or chemical peels or any cosmetic anti-aging treatments to the target areas within six months of the study treatment. 3. history of surgical procedures to target areas, including removal of benign or malignant skin cancers that, in the opinion of the investigator, may confound study results. 4. participant with a history of heavy smoking, alcohol or drug abuse or steroid treatment. 5. pregnant or breast-feeding females. 6. history of anaphylaxis or allergic reactions to any constituent of the study product and/or local anesthetics, and/or history of severe abnormal drug reaction. 7. those who have participated in clinical trials of other investigational drugs within 3 months before the study treatment. 8. those who are not suitable for subcutaneous injection and biopsy. 9. any condition that the investigator or primary physician believes may not be appropriate for participating the study.

Keywords: spot-mrna01 col1a1 mrna evs
effects of different mode of exercise training on type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: randomized study on the comparison between aerobic training versus progressive resistance training over a 2 months period for older adults with type 2 diabetes. the hypothesis is that progressive resistance training is just as effective as aerobic training on hba1c and could be an alternative training for those older diabetic patients who cannot participate in aerobic exercise.

many studies have shown the importance of aerobic training with respect to management of diabetes. however adoption of aerobic activities may be challenging for some individuals with diabetes, especially the elderly and the obese. there is increasing interest in resistance training and no study have looked at direct comparison between the two. subjects with diabetes but is generally sedentary (determined by means of a questionnaire) were recruited and randomized in one of the two groups. subjects are supervised in a group and a completer is defined as one who completed 18 sessions within 8 weeks.

Eligibility criteria:
inclusion criteria: * aged 50 years and above, * hba1c between 8 to 10 % in the past one month, * sedentary, * able to continuously walk for at least 20 minutes and climbed one flight of stairs unaided without stopping were eligible for participation. exclusion criteria: * uncontrolled diabetes mellitus with hba1c more than 10% or if escalation of treatment of glycemic control or dyslipidemia was likely to be necessary over the 2 months training period period, * congestive cardiac failure, unstable angina or acute myocardial infarction within the last one year, * proliferative diabetic retinopathy, * uncontrolled hypertension, * advanced arthritis likely to limit mobility or participation in prescribed exercises, * respiratory conditions such as asthma and chronic obstructive lung disease, * significant proteinuria or chronic renal insufficiency, * received drugs for the treatment of obesity or very low caloric diet (vlcd, less than 1000 kcal/ day), * renal disease and * inability to monitor glucose level or comply with exercise program.

Keywords: diabetes mellitus randomized control trial exercise hemoglobin a, glycosylated
slnd or not in ct1 ggo invasive lung adenocarcinoma (ectop-1009)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a study from eastern cooperative thoracic oncology project, numbered as ectop-1009. systematically mediastinal lymph node dissection or not in clinical stage t1 ground-glass dominated invasive lung adenocarcinoma: a multi-center, prospective clinical trial

patients will be evaluated for inclusion criteria and exclusion criteria, and then they will sign informal consent if desired. he/she will be randomly assigned to the intervention according to a prepared random tables. patients in the systematically mediastinal lymph node dissection (slnd) group will receive systematically mediastinal lymph node dissection, while those in the non-slnd group will not receive mediastinal lymph node dissection. the primary endpoint is 3-year disease-free survival (dfs). the sample size was estimated with reference to our previous data, in which the 3-year dfs was 96.6% for patients diagnosed with ct1 ground glass opacity (ggo) dominated invasive lung adenocarcinoma and underwent slnd. we assumed that if 3-year dfs of patients in non-slnd group was over 91.6% , then we would deem the non-slnd group to be non-inferior to the slnd group. the sample size was estimated to be 638. in order to render the number of recruited patients for each tumor location conform to the actual distribution, we designed a random table for each tumor location. in our previous study, for ct1 ggo dominated invasion lung adenocarcinoma, tumor in the left upper lobe, left lower lobe, right upper lobe, right middle lobe and right lower lobe accounted for 24.7%, 13.2%, 37.6%, 6.6% and 17.9%, respectively. therefore, the random number table for left upper lobe, left lower lobe, right upper lobe, right middle lobe and right lower lobe included 158 patients, 84 patients, 240 patients, 42 patients and 114 patients, respectively. the total number of patients enrolled was designed to be 638.

Eligibility criteria:
inclusion criteria: * clinical stage t1n0m0 and planned curative surgery. * a single lesion detected on computed tomography (ct) scan featured as ground glass nodule(ggo) and c/t ratio ≤0.5. * age 18 to 75. * patients who have signed the informed consent form. exclusion criteria: * other than invasive adenocarcinoma by pathological analysis. * other than lobectomy or sublobar resection in surgical procedure. * not complete resected or curative intent. * patients who have history of other malignant tumors. * patients who have history of thoracic surgery. * patients who have received radiation, chemotherapy or other treatments previously.

Keywords: invasive lung adenocarcinoma; systematically mediastinal lymph node dissection; ground-glass nodule
innovative training program for elderly in need of care individuals

Conditions: Poor Performance Status; Muscle Weakness

Summary: the goal of this randomized controlled study was to examine the effects of a 8 weeks innovative training regime (stochastic resonance whole-body vibration \[sr-wbv\] and virtual virtual games \[vg\]) in the skilling up phase on physical performance and strength in elderly in need of care population.

sensorimotor and strength exercise are methods to increase strength \& power in the field of geriatrics. the question that arise what exercises are best suited to and most effective for elderly in need of care individuals. such populations are advised first to enter a "skilling up program" before more traditional forms of training exercises are implemented. goals in the skilling up phase: improvement in neuromuscular control, postural control and strengthening of large muscle groups of the lower extremity. the aim of the study in the skilling up phase: study the effect on physical performance study the effects on muscle strength.. the participants will be recruited in canton bern - switzerland and will be randomly allocated to an intervention group or sham group.

Eligibility criteria:
inclusion criteria: * rai (resident assessment instrument) \>0 * live in canton bern * in terms of training load be resistant. exclusion criteria: * acut joint disease, acut thrombosis, acute fractures, acute infections, acute tissue damage, or acute * surgical scars * seniors with prosthesis. * alcoholic * acute joint disease, activated osteoarthritis, rheumatoid arthritis, acute lower limb * acute inflammation or infection tumors * fresh surgical wounds * severe migraine * epilepsy acute severe pain
rituximab for htlv-1-associated myelopathy

Conditions: HTLV-1-associated Myelopathy

Summary: neuroprotective or anti-inflammatory strategies are invaluable in htlv-1-associated myelopathy due to its rapid progression. we evaluated the efficacy of rituximab in patients with htlv-1-associated myelopathy.


Eligibility criteria:
inclusion criteria: * age 18-80 years * patients htlv-1-associated myelopathy (tropical spastic paraparesis) exclusion criteria: * anticipated survival of at least 3 years * inability to undergo neuroimaging with magnetic resonance * clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (lfts \>2x normal, coagulopathy as described) * comorbid conditions likely to complicate therapy including but not limited to the following: a history of new york heart association class ii, iii, or iv congestive heart failure; end-stage acquired immune deficiency syndrome * pregnancy * malignancy (history of or active) * concomitant use with antineoplastic, immunosuppressive or immune modulating therapies
a post-intervention surveillance study regarding the acquisition rate of esbl-kp, ecoli

Conditions: Infection

Summary: to determine the acquisition rate of esbl producing e. coli or k. pneumoniae, post- intervention in the selected medical centres

this is post-interventional study to follow the acquisition rate of esbp producing e. coli or k. pneumoniae at the sites involved in a previous interventional study.

Eligibility criteria:
inclusion 1. all patients admitted or transferred to icu/burn unit. 2. patients of either sex, 18 years of age or older. exclusion patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

Keywords: esbl
auto-antibodies prevalence and cd1 role in gaucher disease

Conditions: Gaucher Disease

Summary: hypergammaglobulinaemia is frequently observed in type 1 gaucher disease (gd1), being either polyclonal or monoclonal gammopathies. polyclonal hypergammaglobulinemia may be related to the presence of autoantibodies. the clinical significance of such antibodies is questioned in gaucher disease (gd), as some cases of immunologic thrombocytopenia and autoimmune hemolytic anemia have also been reported. objectives: to evaluate the prevalence of autoantibodies and autoimmune diseases in gd1 patients, we conducted a multicenter national study. the investigators investigated whether there was a link between splenectomy, genotype, therapeutic options and the presence of these autoantibodies.they also investigated whether there was a correlation with some clinical manifestations of gd1


Eligibility criteria:
for gd1 patients inclusion criteria: * adult patients \>= 18 years old * gaucher disease type 1, proved by low betaglucosidase, with or without treatment * patients must have read, understood and signed informed consent. exclusion criteria: * under 18 years old * pregnant or breast-feeding * patients under administrative control * prisoners * patients without social rights * emergency hospitalization
observational, data collection study for subjects with diabetes using insulin injections

Conditions: Diabetes Mellitus

Summary: this is an observational, multicenter prospective study including up to 260 subjects with type 1 or type 2 diabetes who use insulin injections (either basal insulin only or multiple daily injections (mdi)) and cgm or smbg to manage their diabetes. the study aims to generate the database needed for future development and verification of insulin-glucose modules of subjects with diabetes using insulin injections. during the study, subjects will continue their regular diabetes management using their regular glucose monitoring method (either cgm or smbg), insulin injections and oral medication (as applicable). subjects will be requested to document glucose levels and insulin delivery during basal only or basal/bolus insulin treatment. in addition, subjects will have their daily activities recorded (meals, physical activity etc) using electronic log (implemented on the cgm/fgm receiver, dedicated app, neura app and/or other logbooks). data will be captured during regular daily life using insulin connected pens and daily diary application software, for a period of 1 month.


Eligibility criteria:
inclusion criteria: 1. documented t1d or t2d for at least 1 year prior to study enrolment 2. t1d: subjects aged 1 year or older 3. t2d: subjects aged 30 years or older 4. a1c at inclusion ≤ 10% 5. subjects using basal-bolus mdi therapy or basal insulin only - basal insulin lantus or tregludec and any short acting insulin. * t2d: insulin pumps will also be accepted. 6. t2d: bmi ≥ 25 kg/m2 7. subjects willing to follow study instructions: 1. for smbg users: measure capillary blood glucose at least 4 times a day and twice a week 7-point profile. document blood glucose level, insulin delivery, meals and daily activities. optional: wear blinded cgm. 2. for cgm users: document insulin delivery, meals and daily activities. optional: measure capillary blood glucose in addition. 8. adult subjects or parents of pediatric subjects willing and able to sign a written informed consent form. exclusion criteria: 1. an episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment. 2. concomitant diseases/ treatment that influence metabolic control (except diabetes treatment for t2) or any significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise subject's safety 3. t2d: egfr \< 60 4. participation in any other interventional study 5. female subject who is pregnant or planning to become pregnant within the planned study duration 6. t1d: subject is in the "honeymoon" phase - i.e. less than 0.5 insulin units/kg per day. 7. drug or alcohol abuse.